IDROSSICLOROCHINA AUMENTA LA MORTALITA’ PER COVID-19: UNA META-ANALISI COLLABORATIVA DA “NATURE COMMUNICATIONS”

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials Cathrine Axfors, Andreas M. Schmitt. Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival…

BAYES E VACCINO PFIZER-BIONTECH: UNA ATTENTA ANALISI SULLA EFFICACIA. DO YOU BAYES ? PARTE SECONDA

Bayesian Statistics of Efficacy of Pfizer-BioNTech COVID-19 Vaccine — part II Reproducing original results Bartek Skorulski Part II (this post) Reproducing statistics from the article Additional parameter θ Prior distribution of θ and an adjustment of occurrences Credible Interval for posterior Vaccine Efficacy COVID-19 occurrence in participants with and those without prior evidence of infection…

BAYES E VACCINO PFIZER-BIONTECH: UNA ATTENTA ANALISI SULLA EFFICACIA. DO YOU BAYES ? PARTE PRIMA

Bayesian Statistics of Efficacy of the Pfizer-BioNTech COVID-19 Vaccine — part I Vaccine Efficacy and Beta-binomial model Bartek Skorulski Posterior distribution with 95% Credible Interval: (90.8–97.9%) ,,,,,,,,,our results are that the vaccine efficacy is 95% with 95%-Credible Interval equal to (90.8–97.9%). You can get slightly different results but they should be very close. Those results…

NUOVA MODALITA’ PER IL REPORT DI META-ANALISI : “PRISMA STATEMENT ” 2020

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Matthew J. Page et al. Abstract The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past…